Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Discovery of Varicella zoster virus circular RNA with nanopore long-read sequencing

ABSTRACT: Discovery of Varicella zoster virus circular RNA with nanopore long-read sequencing

PROVIDER: PRJNA1057831 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR27368849.fastq.gz	Fastqsanger.gz

Items per page:

1 - 1 of 1

Similar Datasets

Discovery of Varicella zoster virus circular RNA with nanopore long-read sequencing

Project description:Varicella-zoster virus (VZV), an alphaherpesvirus, causes chickenpox (varicella) in young children with an annual minimum of 140 million new cases and herpes zoster in senior, a painful and debilitating disease with 3-5‰ incidence. A complex structural transcriptome of VZV, which numerous novel transcripts, transcript isoforms, and unknown splice events are found during cell infection. Circular RNA (circRNA), a newly important component of the transcriptome, is increasing discoveries of circRNA function in mammalian cells. However, VZV encoded circRNA remains unexplored. The code used in this study and extended data are available from the GitHub repository (https://github.com/ShaominYang/VZV_circRNA)

2024-04-27 | GSE252124 | GEO

Discovery of Varicella zoster virus circular RNA with short read sequencing

Project description:Varicella-zoster virus (VZV), an alphaherpesvirus, causes chickenpox (varicella) in young children with an annual minimum of 140 million new cases and herpes zoster in senior, a painful and debilitating disease with 3-5‰ incidence. A complex structural transcriptome of VZV, which numerous novel transcripts, transcript isoforms, and unknown splice events are found during cell infection. Circular RNA (circRNA), a newly important component of the transcriptome, is increasing discoveries of circRNA function in mammalian cells. However, VZV encoded circRNA remains unexplored. In this study we demonstration that VZV derived circRNAs are biologically functional and contributed to viral pathogenesis. Using deep RNA-seq following RNase R treatment, we identified and charactered 35, 076 and 54 human and VZV pOka strain circRNAs respectively from VZV infected neuroblastoma cell (SH-SY5Y).

2024-04-27 | GSE223870 | GEO

Discovery of Varicella zoster virus circular RNA with short read sequencing

Project description:Discovery of Varicella zoster virus circular RNA with short read sequencing

| PRJNA928710 | ENA

A transcriptomic analysis of SH-SY5Y cells with Varicella-Zoster Virus-Infected

Project description:In this study, we screened the differentially expressed genes (DEGs) in SH-SY5Y cells with Varicella-Zoster Virus-Infected using RNAseq technique to explore the molecular mechanisms of Herpes zoster pain

2021-05-12 | GSE141932 | GEO

Varicella-Zoster Virus (VZV) quiescent and productive infection of neurons derived from human embryonic stem cells

Project description:quiescent and productive infection of varicella zoster virus in human embryonic stem stem cell-derived neurons

2015-06-22 | E-MTAB-3635 | biostudies-arrayexpress

T-Cell Responses to Varicella Zoster Virus

Project description:T-Cell Responses to Varicella Zoster Virus

| PRJNA314260 | ENA

Human alphaherpesvirus 3 (Varicella zoster virus)

Project description:Human alphaherpesvirus 3 (Varicella zoster virus) Raw sequence reads

| PRJNA784638 | ENA

Inhibitory effect of Alantolactone against varicella-zoster virus in vitro

Project description:Background : Varicella-zoster virus (VZV), a member of the α-herpesvirus family, is known for causing two distinct diseases: chickenpox (varicella) during the primary infection and shingles (zoster) due to reactivation of the virus later in life. Currently, there were vaccines available to prevent VZV infection, but it is not universally effective, and antiviral treatments for VZV are limited and may come with significant side effects. Thus, development of novel therapeutics is urgently needed. Methods: In the current study, we identified a naturally occurring ALT that inhibits replication of recombinant VZV in human diploid fibroblast (WI-38 cells) and Adult Retinal Pigment Epithelial cell line-19 (ARPE-19 cells) through Western blotting, qPCR and plaque assays. The time-of-addition experiment was carried out to identify the stage at which ALT acted. Meanwhile, the transcriptome was applied for the initial exploration of the mechanism underlying anti-VZV activity. Results : We established a screening model for anti-VZV compounds from which we screened ALT with good antiviral efficacy. Our findings revealed that ALT alleviated cytopathic changes, reduced viral titres, and inhibited the expression of viral genes and proteins in WI-38 cells and ARPE-19 cells. Furthermore, our data showed that ALT inhibits VZV infection at both early and late stages of the viral life cycle. Finally, according to RNA-seq data, multiple inflammatory pathways were involved in this antiviral process, and IL-6 was one of the most critical hub genes. Conclusion : Together, our findings identify ALT as a anti-VZV agent that may prove useful in the treatment of VZV replication.

2025-05-14 | GSE289362 | GEO

Neutrophil extracellular traps and alveolar barrier disruption contribute to varicella pneumonia pathology

Project description:Varicella pneumonia is the most common and severe complication of primary varicella-zoster virus (VZV) infection in adults. Pathogenesis of varicella pneumonia is largely unknown, mainly due to limited availability of clinical specimens and lack of appropriate VZV animal models. Simian varicella virus (SVV) infection of nonhuman primates closely recapitulates clinical and pathogenic features of human VZV disease. This study aimed to elucidate the virus and host factors that contribute to the pathogenesis of varicella pneumonia. The deposited data present changes in gene expression in the lung of SVV-infected cynomolgus macaques (Macaca fascicularis) at 3, 6 and 9 days after infection, and mock-infected control macaques at 3 days after infection.

2020-09-01 | E-MTAB-8485 | biostudies-arrayexpress

Inhibitory effect of Alantolactone against varicella-zoster virus in vitro

Project description:Inhibitory effect of Alantolactone against varicella-zoster virus in vitro

| PRJNA1222786 | ENA